Slow Capital Inc. Sells 1,822 Shares of Johnson & Johnson (NYSE:JNJ)

Slow Capital Inc. lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 11.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 13,705 shares of the company’s stock after selling 1,822 shares during the period. Slow Capital Inc.’s holdings in Johnson & Johnson were worth $1,982,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Foundations Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 5.2% during the 4th quarter. Foundations Investment Advisors LLC now owns 16,575 shares of the company’s stock worth $2,397,000 after purchasing an additional 826 shares during the last quarter. McLean Asset Management Corp increased its position in Johnson & Johnson by 6.2% in the fourth quarter. McLean Asset Management Corp now owns 3,390 shares of the company’s stock worth $490,000 after buying an additional 198 shares during the last quarter. waypoint wealth counsel lifted its position in shares of Johnson & Johnson by 4.0% during the 4th quarter. waypoint wealth counsel now owns 5,092 shares of the company’s stock valued at $736,000 after buying an additional 196 shares during the last quarter. Union Bancaire Privee UBP SA bought a new position in shares of Johnson & Johnson during the 4th quarter worth $85,886,000. Finally, Apexium Financial LP raised its stake in Johnson & Johnson by 108.1% in the 4th quarter. Apexium Financial LP now owns 21,679 shares of the company’s stock valued at $3,135,000 after acquiring an additional 11,262 shares during the period. Institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on JNJ shares. Stifel Nicolaus reduced their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Leerink Partners lowered their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Wolfe Research assumed coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Finally, Raymond James cut their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $170.44.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $152.78 on Friday. The company has a market capitalization of $367.82 billion, a price-to-earnings ratio of 22.97, a PEG ratio of 2.45 and a beta of 0.51. The business has a 50 day moving average of $147.73 and a 200 day moving average of $156.10. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm’s revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.29 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.25%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Insider Buying and Selling

In related news, Director Mark A. Weinberger acquired 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.